The past decade has seen an explosion of research into an emerging arm of the innate immune system, collectively termed the innate lymphoid cell (ILC) family 1, 2 . These studies have defined ILCs as important regulators of immunity, i n f l a m m ation a n d b a r r i er h o m eo s t asis t hr ou gh t h e ir rapid production of effector cytokines in response to tissue-derived signals such as alarmins, neuronal mediators and microbial, dietary or other environmental cues 1, 2 . ILCs are broadly grouped into three main subsets based on their transcription factor expression and cytokine production (Box 1 and reviewed extensively elsewhere 1,2 ). These ILC subsets have unique developmental, phenotypic and functional characteristics.
ILC subsets closely mirror the transcriptional and functional biology of both cytotoxic CD8 + T cells and CD4 + T helper (T H ) cells. However, unlike cells of the adaptive immune system, ILCs can colonize lymphoid and barrier tissue sites during fetal development, do not undergo somatic recombination and lack antigen-specific receptors. Furthermore, ILCs are transcriptionally, epigenetically and functionally poised to rapidly mediate specialized functions in response to subset-specific danger signals 1, 2 . In order to distinguish and dissect the contributions of ILC-derived cytokines from the cytokines produced by T H cell subsets, many initial studies necessarily used mice deficient in adaptive immunity, such as Rag1 −/− mice. Although these experiments were a crucial step forwards in our understanding of fundamental aspects of ILC biology, the approaches used have substantial caveats, including the inability to study ILCs in the context of adaptive immunity or to appreciate the potential interplay between these innate and adaptive lymphocytes.
Analyses of defined patient populations and the development of new mouse models to more selectively target ILCs have indicated a degree of functional redundancy between ILC responses and adaptive immunity during infection [3] [4] [5] [6] . For example, although ILCs are an important source of cytokines during the initial stages of an infection, this function can become dispensable following the establishment of an adaptive immune response, where T cell subsets that can produce identical cytokines outnumber ILCs in the tissue [3] [4] [5] [6] . This redundancy between ILCs and T cells has led to substantial questions regarding the shared biology and evolutionary relationships between these cell types. Indeed, ILCs are conserved among humans, rodents and zebrafish 2, 7, 8 , and associated cytokines or core transcriptional machinery are found in distant ancestors such as bony fish and lampreys 7 . This suggests that retaining ILC-like cells has conferred a distinct evolutionary advantage even in the presence of an adaptive immune system. Therefore, it is tempting to speculate that ILCs have additional and/or unique, non-redundant functions beyond those shared with T cells. In support of this, recent studies have highlighted that subsets of ILCs express multiple factors that functionally modulate adaptive immunity, which together shape the magnitude and quality of an immune response. In this Review, we focus on substantial evidence that implicates ILC family members as previously unappreciated regulators of the adaptive immune system in the context of health and disease. Specifically,
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we focus on group 2 and group 3 ILCs (ILC2s and ILC3s) for which substantial evidence implicates direct communication with the adaptive immune system, whereas less is currently known regarding adaptive immune interactions with group 1 ILCs (ILC1s).
Anatomical distribution of ILCs
Unique spatial and temporal interactions occur between ILCs and adaptive immune cell populations throughout the lifetime of a human. During the fetal period, ILCs promote secondary lymphoid tissue organogenesis and seed unique tissue niches. This has been extensively reported and reviewed in the literature [9] [10] [11] [12] and is not a major focus of discussion below. Rather, we concentrate on the postnatal period where ILC populations undergo expansion and interact with adaptive immune cells during initial exposure to microorganisms and their products. In addition, we review periods of health and disease, where communication between ILCs and adaptive immune cells may crucially control the outcome of immune homeostasis, infection, inflammation or ageing (FIg. 1 ). Defining the anatomical distribution of ILCs throughout these periods enables a better understanding of their functional interactions with adaptive immune cells.
Lymphoid tissues. One of the earliest identified ILC subsets was characterized as CD4 + CD3 − haemato poietic cells that seed sites that give rise to lymphoid tissues during fetal devel opment 9, 11 . These cells express α 4 β 7 integrin and lymphotoxin and are now defined as lymphoid tissue-inducer cells (LTi cells) owing to their essential role in promoting secondary lymphoid tissue organogenesis 10, 12 . The development of LTi cells requires the transcription factor retinoic acid-related orphan receptor-γt (RORγt) 13 , and as such LTi cells are assigned to the ILC3 subset. Furthermore, LTi cells persist after birth and promote the development of tertiary lymphoid structures in the gut, such as cryptopatches and isolated lymphoid follicles, which mature in response to microbiota colonization [14] [15] [16] . In general, LTi cells found in adult mice are termed LTi-like, express high levels of CC-chemokine receptor 6 (CCR6) and are heterogeneous in their expression of CD4. However, fundamental questions remain regarding the long evity, lineage relationships and differential functions of LTi-like cells in adult mammals, the answers to which are hampered by a lack of specific genetic tools.
LTi-like cells are located after birth predominantly within organized lymphoid structures, including draining lymph nodes, Peyer's patches and tertiary lymphoid structures [17] [18] [19] [20] . ILC2s are also found in these tissues and in fat-associated lymphoid clusters 21, 22 . A majority of ILC2s in these sites, and other sites discussed below, are seeded during fetal development or neonatal periods, and they acquire tissue-specific transcriptional signatures. There is variable replacement of these ILC2s across tissues with age, and rapid in situ expansion of ILC2 populations can occur upon infectious or inflammatory challenge 23 (FIg. 1 ). Within lymph nodes, both LTi-like ILC3s and ILC2s selectively localize at inter-follicular regions 19 (FIg. 2 ). These regions surround B cell follicles at the key entry points for the afferent lymphatics and they are also the primary location where interactions between T cells and B cells are initiated. Thus, this localization pattern of ILC3s and ILC2s suggests that they directly encounter recent emigrant lymphocytes from the tissues and might influence T cell-B cell interactions or the initiation of humoral immune responses.
A detailed understanding of the molecular machinery that is required for ILCs to localize to this lymphoid niche is still lacking. LTi cells and adult LTi-like ILC3s express CXC-chemokine receptor 5 (CXCR5), which is required for the generation of Peyer's patches and isolated lymphoid follicles but does not influence the localization of LTi-like ILC3s at the inter-follicular border in established lymph nodes 24, 25 . By contrast, GPR183 (also known as EBI2; a receptor for oxysterols) is required for the localization of LTi-like ILC3s both within intestinal lymphoid structures in the large intestine and at the inter-follicular border of the mesenteric lymph nodes (MLNs) 17, 18, 25 . Notably, the localization of LTi-like ILC3s in cryptopatches in the large intestine is mediated through gradients of 7α,25-dihydroxycholesterol (7α,25-OHC) and maintained through spatial segregation of stromal cell populations expressing either the 7α,25-OHC-generating enzyme CH25H or the 7α,25-OHC-degrading enzyme CYP7B1 (reF. 18 ). The lymphoid niche for ILC3s may also be established before birth, as fetal stromal organizer cells have been found to give rise to adult marginal zone reticular cells and to persist throughout life in close association with ILC3s 26 . In addition, LTi-like ILC3s are commonly characterized by expression of CCR6, and interactions between CCR6 and CC-chemokine ligand 20 (CCL20) are important for the formation of tertiary lymphoid structures in the small intestine but not the colon 14, 27 .
Barrier tissues. Beyond lymphoid structures, ILCs are enriched in barrier tissues of the mammalian body, such as the gastrointestinal tract, airways and skin (FIg. 2) . T-bet + ILC3s expand following colonization with the intestinal microbiota and are found in large numbers Box 1 | The ILC family Group 1 ILCs Group 1 innate lymphoid cells (IlC1s) include classical natural killer (NK) cells and non-NK cells that express the transcription factor T-bet and produce the cytokines IFNγ and tumour necrosis factor to mediate immunity against intracellular pathogens. NK cells are distinguished by co-expression of eomesodermin (eomeS). Dysregulated IlC1 responses have been implicated in the pathogenesis of inflammatory bowel disease (IBD) and rheumatoid arthritis.
Group 2 ILCs
Group 2 IlCs (IlC2s) express high levels of GATA-binding factor 3 (GATA3) and produce the cytokines Il-4, Il-5, Il-9, Il-13 and amphiregulin in response to large multicellular helminth pathogens or protozoa. IlC2s include both a 'natural' subset that is present during homeostasis and an 'inflammatory' subset that is generated during an immune response, and these subgroups exhibit some phenotypic heterogeneity. Dysregulated IlC2 responses can drive allergic disease in the context of asthma and atopic dermatitis.
Group 3 ILCs
Group 3 IlCs (IlC3s) express retinoic acid receptor-related orphan receptor-γt (RoRγt) and produce Il-17A and Il-22 in response to both commensal and pathogenic extracellular microorganisms. IlC3s are heterogeneous and include T-bet + IlC3s that express natural cytotoxicity receptors, CCR6 + IlC3s that are also known as lymphoid tissue inducer-like cells and ex-IlC3s that have lost RoRγt expression and resemble IlC1s. As for other IlC family members, inappropriate IlC3 responses have been implicated in chronic inflammatory disorders, including IBD and multiple sclerosis. 
Tertiary lymphoid structures
organized lymphoid aggregates that develop after birth in response to microbiota colonization or chronic inflammation.
www.nature.com/nri
within the lamina propria of the intestine (FIg. 1 ). This localization pattern is controlled in part through expression of CXCR6 (reF. 28 ). In the skin, ILC2 and ILC3 subsets are located throughout the dermis and epidermis, with some LTi-like ILC3s localizing to hair follicles in a CCR6-dependent manner 29 . ILC2 populations in the lungs expand after birth, are found at branch points in the airways and colocalize with CD4 + regulatory T (T reg ) cells, dendritic cells (DCs) and specialized stromal cells that produce activating cytokines (such as IL-33 or thymic stromal lymphopoietin (TSLP)) 30 . This is a conserved localization pattern for ILC2s, which also includes proximity to blood or lymphatic vessels in multiple tissues, including the skin, adipose tissue, liver, kidney, pancreas and intestine [31] [32] [33] [34] . Together, these findings suggest that conserved sensing of migratory cues establishes residency of ILC subsets in defined microenvironments across multiple tissue sites.
During homeostasis, most ILCs in mice are tissue resident, absent from the circulation and variably replaced from bone marrow haematopoietic progenitors 35, 36 . However, several recent studies suggest that ILCs can migrate through the lymphatics during homeostasis or enter the circulation during infection and inflammation (FIg. 2) . For example, both ILC2s and LTi-like ILC3s migrate in the lymphatics from the intestine to the draining lymph node under steady-state conditions, as shown in photo-convertible mouse studies, and the migration of LTi-like ILC3s in this case depends upon expression of CCR7 (reFs 19, 37 , promote secondary lymphoid tissue organogenesis before birth and, together with group 2 ILCs (ILC2s), seed multiple lymphoid or barrier tissues during fetal development and neonatal periods. Following birth, ILC2 populations expand within tissues and T-bet + ILC3 populations expand in the intestine as a result of colonization by the microbiota and exposure to other environmental stimuli. During this period of tolerance induction during weaning and throughout conditions of homeostasis in healthy adults, ILCs interact with adaptive immunity to promote tissue homeostasis. This occurs primarily through bidirectional interactions. Conversely , in the context of ageing, infection, inflammation or immunodeficiency , ILCs and adaptive immune cells engage in a pro-inflammatory interaction that is a crucial determinant of the immune response. In both of these contexts, interactions involve complex cytokine networks or direct cellular communication via antigen presentation, co-stimulatory molecules and inhibitory molecules. T reg cell, regulatory T cell.
of lymph node-homing receptors to gut-homing receptors on ILCs can occur in the mucosal draining lymph nodes, mediated in part by retinoic acid and DCs 38 . In addition, recent findings suggest that lymph nodes contain both migratory and resident ILC populations and that ILC1s, in particular, have the capacity to recirculate to tissues and peripheral lymph nodes via the blood where they provide IFNγ to aid T cell priming in a sphingosine 1-phosphate (S1P)-receptor-dependent manner 37 . Furthermore, following nematode infection, a unique The ability of innate lymphoid cells (ILCs) to interact with adaptive immune cells and modulate their responses is highly dependent on the colocalization of these cell types within tissues and lymphoid structures. This is best characterized for group 2 ILCs (ILC2s) and group 3 ILCs (ILC3s), which are constitutively found within both mucosal barrier tissues and associated lymphoid tissues. Within the intestinal tissue, ILCs are largely found within either lymphoid structures (such as Peyer's patches or cryptopatches of the small intestine) or the lamina propria. Localization of lymphoid tissue inducer (LTi)-like ILC3s to cryptopatches is controlled through sensing of stromal-derived cues by receptors such as GPR183 (also known as EBI2; a receptor for oxysterols), whereas the localization of T-bet + ILC3s within the intestinal lamina propria is mediated by CXC-chemokine receptor 6 (CXCR6)-dependent homing. Increasing evidence suggests that subsets of ILCs (specifically , inflammatory ILC2s and group 1 ILCs (ILC1s)) can migrate out of tissues via blood vessels in a sphingosine 1-phosphate (S1P)-dependent manner in the context of infection and inflammation and circulate throughout the body to establish residence in peripheral organs, including the lungs. Within multiple peripheral tissues, ILC2s are found localized within 'adventitial cuffs', tissue niches that form around airways and blood vessels and are characterized by stromal cell populations expressing ILC2-activating cytokines. In addition, ILCs can migrate in the lymphatics to draining lymph nodes, such as the intestinal-associated mesenteric lymph node chain, in a CC-chemokine receptor 7 (CCR7)-dependent manner and colocalize at the inter-follicular border between the B cell follicle and the T cell zone. ILCs interact with many types of T cell, including T follicular helper cells, regulatory T cells, T helper 1 (T H 1) cells, T H 2 cells and T H 17 cells; these interactions are described in greater detail in FIgs. 3-5. M cell, microfold cell; SFB, segmented filamentous bacteria. www.nature.com/nri population of IL-25-elicited inflammatory ILC2s enters the circulation and migrates from the intestine to associate with the airways in an S1P-dependent manner 39, 40 . It is important to note that there may be substantial differences between humans and mice, as circulating ILC progenitors are constitutively present in human blood and are thought to differentiate into mature ILCs within tissues 41 . The reasons for these differences between human and mouse ILCs remain an active area of investigation.
Regulation of adaptive immunity by ILCs
Extensive research over the past decade has focused on the role of ILCs as innate sources for the rapid production of effector cytokines during infection or inflammation, but it is increasingly appreciated that ILCs also have important roles in bridging innate and adaptive immune responses. Through various indirect and direct interactions, ILCs can functionally affect the quality and magnitude of adaptive immune responses within complex tissue microenvironments.
Indirect regulation through bystander cells.
ILCs markedly influence adaptive immune responses through several discrete pathways. As highlighted above, LTi cells promote lymphoid tissue organogenesis during fetal development through their production of lymphotoxin. Following birth, ILCs help to maintain homeostatic responses against the microbiota at mucosal barrier surfaces by supporting IgA production in gut-associated lymphoid tissues. This occurs through the provision of surface lymphotoxin-α 1 β 2 heterotrimers by ILC3s, which activate DCs located in the subepithelial dome of Peyer's patches or the lamina propria to express inducible nitric oxide synthase and which subsequently support T cell-independent production of IgA 42, 43 . In addition, ILC3s produce soluble lymphotoxin-α 3 , which activates stromal cells to support T cell homing to the intestine and subsequent CD40L-dependent IgA responses 42, 44 . In the spleen, the production of lymphotoxin and granulocyte-macrophage colony-stimulating factor (GM-CSF) by ILC3s indirectly promotes marginal zone B cell responses by controlling stromal cell and neutrophil homeostasis, respectively 45 . Moreover, following the destruction of stromal cell populations by infection with lymphocytic choriomeningitis virus, ILC3 expression of lymphotoxin-α 1 β 2 supports the restoration of secondary lymphoid tissues, which is crucial to enable adaptive immune responses to secondary infections 46 .
Beyond lymphotoxin, other canonical ILC-derived factors indirectly influence adaptive immune cells (FIg. 3a ). For example, in the context of allergen-induced airway inflammation, ILC2-derived IL-13 promotes the migration of lung-associated DCs to the draining lymph node to subsequently facilitate priming of naive CD4 + T cells into T H 2 cells 47 . This mechanism is not limited to initial allergen exposure, as ILC2-derived IL-13 also stimulates airway DCs to produce CCL17, which drives memory T cell migration to the airways during secondary challenge with an allergen 48 . A similar paradigm may exist for natural killer (NK) cells or ILC1s, which rapidly produce IFNγ following exposure to intracellular pathogens 49, 50 , although the mechanisms of action are less well characterized and it remains unclear whether IFNγ acts directly on CD4 + T cells or indirectly via associated myeloid cells (FIg. 3b ). In the context of autoimmunity, a T-bet + ILC population was demonstrated to promote T cell entry into the central nervous system through the production of pro-inflammatory cytokines, chemokines and matrix metalloproteinases, which collectively facilitate neuro-inflammation 51 . However, it remains unclear whether this ILC population represents T-bet + NK cells, ILC1s or ILC3s.
ILC3-derived cytokines also augment adaptive immunity through several distinct mechanisms (FIg. 3c ). Production of IL-22 can have wide-ranging tissueprotective effects 52 . This pathway is engaged early following extracellular pathogen encounter and is necessary to promote intestinal immunity before the initiation of an adaptive immune response [52] [53] [54] . ILC3 production of IL-22 is also induced following exposure to the commensal microbiota and is necessary to modulate intestinal barrier function, control the composition of the microbiota and influence systemic metabolism 1, 2, 52, [55] [56] [57] [58] [59] . The effects of this pathway on adaptive immunity are indirect and diverse. For example, one study has shown that ILC3derived IL-22 promotes the production of acute phase proteins such as serum amyloid A (SAA) by intestinal epithelial cells, which leads to SAA-dependent induction of microbiota-specific T H 17 cells in the small intestine 60 (FIg. 3c) . Conversely, other studies suggest that ILC3derived IL-22 limits immune activation or tissue damage following encounter with pathogenic or commensal microorganisms, subsequently preventing the activation of local T cells 52, 58, 61 . It remains possible that these diverse outcomes are context or location dependent and may need to be revisited as more selective approaches emerge to target ILC3s in the presence of adaptive immunity.
Another important aspect of intestinal barrier homeostasis is the ability to induce and maintain tolerance to the microbiota or dietary antigens. This is achieved in part by the induction and maintenance of peripheral T reg cell populations, which promote an immunosuppressive environment in the gut. An increasing body of evidence suggests that tissue-resident ILC3s have crucial roles in communicating with T reg cells both indirectly and directly (FIg. 3c ). For example, it was shown that microbiota-sensing macrophages produce IL-1β and induce GM-CSF expression by ILC3s 62 . ILC3-derived GM-CSF subsequently promotes IL-10 and retinoic acid production by intestinal macrophages to support local T reg cell conversion and maintain a tolerogenic environment in the large intestine 62 . Of note, GM-CSF produced by cells resembling ILC2s has also been implicated in the amplification of T H 17 cell-mediated joint inflammation 63 , which suggests that GM-CSF might be produced by multiple ILC subsets with varying effects. Collectively, these results highlight how ILCs have effects on multiple other innate, epithelial and stromal cell compartments to shape adaptive immune responses throughout the mammalian body.
Direct regulation through soluble mediators.
In addition to indirect interactions mediated through bystander cells, ILCs produce multiple soluble factors that directly influence adaptive immunity in the context of health and disease (FIg. 3c ). For example, we recently showed that ILC3s are the dominant source of IL-2 that is induced by macrophage-derived IL-1β following MYD88-and NOD2-dependent sensing of the microbiota in the small intestine 64 . ILC3-derived IL-2 supports the population size of peripherally induced T reg cells in the small intestine and is essential to maintain tolerance to dietary antigens 64 . ILC2s also produce several soluble factors that can directly modulate CD4 + T cell responses (FIg. 3a) . Limited evidence suggests that ILC2-derived IL-4 is important for promoting T H 2 cell differentiation or inhibiting T reg cell responses in the context of intestinal parasite infections or food allergy, respectively 65, 66 . Furthermore, ILC2s can also produce IL-2 during homeostasis or following allergen challenge, and IL-2 from both innate and adaptive sources is a crucial cofactor in the activation of ILC2s 20, 67 . ILCs may also directly modulate humoral immune responses through cytokine-mediated effects on B cells. For example, ILC2s produce IL-5 and IL-6, which might support the self-renewal of B1 cells or enhance the production of IgM and IgA 21, 22 . Similarly, ILC3 production of the human B cell survival factor BAFF (also known as TNFSF13B) supports marginal zone B cell responses in the spleen 45 . Together, these findings suggest that, in addition to their primary roles in producing effector cytokines during infection or inflammation, ILCs also directly modulate adaptive immunity through the release of soluble factors in the local tissue milieu. and LTβ to indirectly support B cell class switching and IgA production through effects on stromal cells. ILC3s in the spleen express the B cell survival factors BAFF and APRIL , but this has not yet been reported at mucosal sites. In addition, multiple reports have described a complex communication between ILC3s, macrophages and T reg cells in the intestine, which reinforces tolerance and tissue homeostasis. This is achieved either directly through the secretion of IL-2 by ILC3s, which provides crucial survival signals to T reg cells, or indirectly through the secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF). The latter pathway results in a feedback loop, whereby macrophages respond to GM-CSF by producing IL-10 and retinoic acid (RA) to further reinforce T reg cell conversion and maintenance. ILC3 production of IL-22 has been linked to the production of serum amyloid A (SAA) by intestinal epithelial cells, which supports T H 17 cell responses. T H 17 cell production of IL-17A induces antimicrobial responses by intestinal epithelial cells and controls the composition of the microbiota, including limiting colonization with segmented filamentous bacteria (SFB).
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Contact-dependent interactions
A key conceptual advance in ILC biology was the discovery that ILCs have the potential to function as antigen-presenting cells and directly modulate adaptive immune responses (FIg. 4) . Early studies identified that fetal LTi cells express MHC class II molecules 11 . Renewed interest in the ILC family over the past decade has led to further investigation of the potential antigen-presenting functions of ILC subsets.
Antigen presentation by ILCs. At steady state, LTi-like ILC3s in the MLNs and large intestine constitutively express MHC class II molecules at levels comparable with other professional antigen-presenting cells and can acquire, process and present antigens 68 . However, in contrast to DCs, MHC class II + ILC3s in the healthy intestine lack classical co-stimulatory molecules such as CD40, CD80 and CD86 and are unable to induce naive T cell proliferation 68 . Rather, through a series of in vitro and in vivo studies, LTi-like ILC3s were found to suppress effector CD4 + T cell responses in the gut (FIg. 4a) . Consistent with this, mice with an ILC3-specific deletion of MHC class II expression had dysregulated T H 1 cell and T H 17 cell responses to the commensal microbiota and spontaneous inflammation in the large intestine [68] [69] [70] . These studies were a key advance in defining LTi-like ILC3s as a novel antigen-presenting cell type, and they defined a novel pathway that regulates microbiota-specific CD4 + T cells in the intestine 68 
questions regarding the mechanisms by which ILCs acquire antigens, whether ILCs influence other types of T cell response (such as T H 1 cells, T H 2 cells or T reg cells) through antigen presentation and the role of antigen-presenting ILCs during infection or inflamma-
tion. Furthermore, one recent study described an atypical MHC class II + ILC3-like population in peripheral lymph nodes that expresses the autoimmune regulator protein (AIRE) 71 . However, the functional significance of this cell type or the expression of AIRE in ILC-like cells remains unclear, and it should be noted that only a minority of antigen-presenting RORγt + cells in the lymph nodes express AIRE. Recent advances suggest that MHC class II + ILC3s colocalize and interact with T follicular helper (T FH ) cells in the MLNs. The absence of antigen presentation by ILC3s in MLNs resulted in expansion of T FH cell popu lations, enhanced de novo germinal-centre reactions and increased IgA class switching 25 (FIg. 4a ). The number of IgA-secreting plasma cells in the colon was increased in mice lacking ILC3-specific expression of MHC class II molecules, and increased IgA production was found preferentially to target bacterial species residing within the colonic mucosa. This suggests that under steady-state conditions, ILC3-mediated antigen presentation may further promote mutualism with the mucosal microbiota by limiting T cell-dependent IgA production that otherwise leads to the exclusion of mutualistic species from the mucosal niche 25 . Taken together, these studies suggest that antigen presentation by MLN-resident ILC3s suppresses multiple aspects of inflammatory T cell responses towards the microbiota under conditions of immune homeostasis.
Conversely, antigen-presenting ILC3s have been shown to promote adaptive immune responses in the context of vaccination, chronic inflammation or lymphopenia 72 (FIg. 4b) . Notably, stimulation of in vitro-generated ILC3-like cells with IL-1β was shown to upregulate expression of MHC class II and co-stimulatory molecules, including CD40 and CD80, which was associated with the ability of these cells to promote antigen-specific CD4 + T cell responses 72 . This study may highlight tissue-specific roles for antigen-presenting ILC3s, as IL-1β did not promote the expression of co-stimulatory molecules on ILC3s directly isolated from the gastrointestinal tract and it was not required for high levels of constitutive MHC class II expression in this context 68, 69 . Therefore, additional investigations are required to determine what causes ILC3s to promote versus inhibit CD4 + T cell responses and whether these functions are mediated by the same ILC3 subset or by unique subsets that arise only in inflammatory environments.
Although ILC3s seem to be the main antigenpresenting ILC subset under homeostatic conditions, MHC class II expression has also been reported on ILC2s, particularly in response to alarmins (FIg. 4c) . A subset of ILC2s induced by either IL-25 or IL-33 have been reported to express genes associated with antigen presentation, including H2-Ab1 and Cd74, and MHC class II levels on ILC2s can be further augmented by the trogocytosis of antigen-containing MHC class II complexes from professional antigen-presenting cells 20,73-75 .
MHC class II + ILC2s from IL-33-treated mice also expressed CD80, and to a lesser extent CD86, and promoted T cell responses in vitro and in vivo 20, 75 .
In addition, ILC subsets can express lipid antigenpresentation molecules of the CD1 family. Most notably, LTi-like ILC3s from mice express CD1D and can present lipid antigens to activate invariant natural killer T cells (invariant NKT cells) in vitro and in vivo 76 , and human ILC2s in the skin express CD1A following stimulation with TSLP and activate CD1A-responsive T cell populations during Staphylococcus aureus infection 77 . These results show that both ILC3s and ILC2s have the potential to augment multiple aspects of adaptive immunity through direct antigen presentation.
Auxiliary surface molecules on ILCs.
The consequences of ILC interactions with T cell subsets seem to differ depending on the ILC subset, anatomical location and context of the encounter. This may, in part, be further regulated by the presence or absence of secondary signals, such as co-stimulatory or auxiliary molecules. Besides classical co-stimulatory mol ecules, ILC subsets express several auxiliary activating and inhibitory molecules with the capacity to modulate interactions with adaptive immune cells (FIg. 4b) , including a range of tumour necrosis factor receptor (TNFR)-family molecules. For example, LTi-like ILC3s express the TNFRfamily molecule RANK (also known as TNFRSF11A) while simultaneously expressing the cognate ligand RANKL (TNFSF11), which regulates cell clustering in intestinal lymphoid structures through homotypic interactions 78 . Furthermore, intestinal ILC3s recognize LIGHT (TNFSF14), on a yet to be identified cell type, through expression of HVEM (TNFRSF14), which modifies cytokine production in the context of infection 79 . ILC1s and ILC2s also express GITR (TNFSF18), which supports their effector functions [80] [81] [82] .
By contrast, ILC3 expression of the TNFR-family ligands OX40L (TNFSF4) and CD30L (TNFSF8) has a key role in modulating adaptive immune cell function through cognate interactions with OX40 (TNFRSF4) and CD30 (TNFRSF8), respectively, on T cell subsets [83] [84] [85] [86] . LTi-like ILC3s may support the formation of memory T cells through direct OX40L-and CD30L-mediated interactions, which suggests that this ILC subset may have nuanced roles in modulating different stages of the adaptive immune response 83, 87 . Furthermore, in an inflammatory and lymphopenic environment, ILC3specific expression of OX40L is induced by TL1A (TNFSF15) expressed by CX 3 CR1 + mononuclear phagocytes, and subsequently promotes a T H 1 cell response 88 (FIg. 4b) . By contrast, ILC3 expression of OX40L may support the maintenance of OX40-expressing intestinal T reg cells within cryptopatches in the presence of lymphopenia but the absence of inflammation 89 . In all of these studies, it remains unclear whether modulation of adaptive immune responses by CD30L or OX40L additionally requires direct antigen presentation by MHC class II + ILC3s and what subsets of ILC3s mediate these functions.
Similarly, ILC2s may also acquire OX40L expression upon stimulation to support OX40 + T H 2 cell and T reg cell responses in the airways following helminth infection Trogocytosis A process whereby cellular interaction results in the transfer of a surface protein from a donor cell to a recipient cell and continued expression of that protein on the surface of the recipient cell.
Invariant natural killer T cells (Invariant NKT cells).
A population of T cells that express surface molecules shared with natural killer cells and a restricted αβ T cell-receptor repertoire.
www.nature.com/nri or allergic airway inflammation 90 (FIg. 4c) . OX40L therefore seems to be a common factor through which ILCs interact with multiple subsets of CD4 + T cells. In addition, ILC2s are characterized by surface expression of inducible T cell co-stimulator (ICOS) but also express ICOS ligand (ICOSL), which reinforces cell survival and effector function in ILC2s themselves through homotypic interactions. Furthermore, ICOS expression by ILC2s supports T reg cell accumulation in response to IL-33 through engagement of ICOSL on the T reg cells 30, 91 (FIg. 4c) . Intriguingly, T reg cells in the gut and adipose tissue also respond to IL-33, which suggests that responses by both T reg cells and ILC2s could be coordinated through competition for activating cues 92, 93 .
As noted above, both ILC2s and ILC3s are located in the inter-follicular niche of lymph nodes, where they may interact with multiple adaptive immune cell populations, including T FH cells, which themselves express ICOS, OX40 and programmed cell death 1 (PD1). However, whether ILCs further modulate T FH cells and subsequent B cell responses through these pathways remains poorly understood. Evidence suggests that ILC3s directly augment B cell responses through expression of CD40L and Notch ligands 45, 94 . Multiple ILC subsets express the inhibitory molecule programmed cell death 1 ligand 1 (PDL1), and expression of PDL1 on ILC2s was surprisingly found to enhance rather than suppress interactions with T H 2 cells following helminth infection 95 . ILC progenitors and mature cells in the periphery also express PD1, which suggests that ILCs themselves may be sensitive to PDL1-mediated inhibition 96 . In line with this, PD1 has been reported to negatively regulate ILC2s in mice and humans 97 . Further studies are required to determine whether the expression of the cognate ligands for these pathways by ILC2s and ILC3s enables direct modulation of specific T H cell subsets or B cells. Moreover, the expression of checkpoint molecules on ILC subsets raises the possibility that these cells provide inhibitory signals in the context of cancer, where checkpoint blockade has shown unprecedented promise as a therapeutic approach 98 .
Regulation of ILCs by adaptive immunity
We have discussed the growing body of evidence that supports a role for ILCs in directly and indirectly modulating the adaptive immune system. Conversely, emerging studies indicate that the adaptive immune system modulates ILC function (FIg. 5 ). Compelling recent evidence shows that lack of the adaptive immune system, specifically T cells, results in the hyperactivation of ILC3s in the small intestine in response to microbial colonization 56, [99] [100] [101] . These reciprocal interactions between ILCs and adaptive immunity may be crucially important in terms of establishing homeostasis during initial colonization of the intestine by the microbiota, when ILCs are the first lymphocytes to encounter microbial stimuli and are necessary to respond before the development of an adaptive immune response 56 . Furthermore, these findings and others have led to the hypothesis that ILCs are crucial pioneers that establish the lymphoid or tissue niches in early-life development, which subsequently have long-term consequences for immune homeostasis 102 .
T cell-derived effector cytokines also cross-regulate ILC responses during an immune response. For example, IFNγ directly limits the proliferation of ILC2s and immunopathology mediated by type 2 immune responses in the airway 30, 36, 103, 104 , and T H 17 cells indirectly limit intestinal ILC3 responses by controlling the intestinal microbiota 56 . In addition, T reg cells have a key role in regulating ILC3 responses as the transfer of FOXP3 + T reg cells prevents the hyperactivation of ILC3 responses in the small intestine of Rag1 −/− mice 56 . Mechanistically, lymphocyte activation gene 3 (LAG3) on T reg cells interacts with MHC class II molecules on the surface of CX 3 CR1 + macrophages to inhibit the production of IL-23 (reFs 56, 99 ). T reg cells also suppress NK cell and ILC1 responses in multiple contexts by depriving them of IL-2 (reFs [105] [106] [107] ). This may reflect a general competition for pro-survival cytokines between innate and adaptive lympho cytes, which can have consequences for the population expansion of B cells or T cells and limit homeostatic proliferation in the context of lymphopenia 69, 108, 109 .
Interactions with adaptive immunity do not always limit subsequent ILC responses and may occur in a tissue-specific manner. For example, in contrast to interactions in the intestine 56, [99] [100] [101] , studies indicate that T cells promote the accumulation of ILC3s in the MLNs and that B cells support ILC3 numbers in the spleen 19, 110 . Adaptive immunity also augments ILC responses as a result of direct cellular contact. For example, CD4 + T cells enhance cytokine production by ILC2s following cognate interactions with MHC class II molecules and subsequent provision of IL-2 by the T cells 20, 75 . Similarly, ICOS-ICOSL interactions between ILC2s and T reg cells not only regulate T reg cells, as discussed above, but also cross-regulate cytokine production by ILC2s, together with T reg cell production of IL-10 and transforming growth factor-β (TGFβ) 30, [111] [112] [113] . This suggests that there is bidirectional communication between these cell populations in response to IL-33. By contrast, MHC class II-dependent interactions between ILC3s and CD4 + T cells have no apparent effect on ILC3 production of IL-22 (reFs 68,69 ); however, the presentation of lipid antigen by ILC3s in the context of CD1D was found to augment IL-22 production, which suggests that NKT cells support ILC3 function following activation 76 . Together, these findings suggest that reciprocal interactions between T cells and ILCs shape the magni tude and quality of ILC responses in multiple tissues and contexts. Additional investigation is required to explore the nature of these interactions and the effector molecules that facilitate this dialogue in health and disease (Box 2).
Human health and disease
ILCs have increasingly been implicated in the pathogenesis of a broad range of chronic infectious, inflammatory or metabolic diseases in humans 1,2 . This can occur through ILC population expansion and production of pro-inflammatory cytokines in response to damage-associated or inflammatory cues, or through loss of protective ILC responses in the context of a maladapted immune system, genetic predisposition and/or
Type 2 immune responses
Immune responses that develop in response to parasitic helminth or allergen exposure and are characterized by cells expressing the transcription factor gATA-binding factor 3 (gATA3), the cytokines IL-4, IL-5 and IL-13 (such as T helper 2 cells and group 2 innate lymphoid cells) and infiltration of eosinophils, mast cells and/or basophils.
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Inflammatory bowel disease.
The contribution of ILCs to human disease is perhaps most extensively investigated in the context of inflammatory bowel disease (IBD), for which many of the genetic polymorphisms that are linked to disease directly implicate dysregulated type 3 immune responses, such as those mediated by T H 17 cells and ILC3s, in the pathogenesis of IBD 114, 115 . Early reports speculated that ILC3s have a crucial role in maintaining homeostasis in the healthy human intestine, with human ILC3s shown to express IL-2 and IL-22 in response to microbial stimulation 116 . Indeed, ILC3s are fundamentally altered in the inflamed human intestine. Several early studies described increased ILC3 numbers or effector responses in the intestines of patients with IBD 117, 118 . By contrast, other studies have described a marked reduction in the number of ILC3s in the inflamed intestine of patients with IBD relative to multiple control samples, which may result from the conversion of ILC3s to ILC1s that is driven by IL-12 and reversed by IL-23 (reFs 119, 120 ). These observations potentially reflect similar subset transitions that have been characterized for mouse ILCs 121, 122 . The differences between the reports showing upregulation or downregulation of ILC3 responses in patients with IBD could result from the new appreciation of ILC1s or an inability to carefully examine for ILC3 heterogeneity in humans. We have shown that ILC3s isolated from the large intestine of paediatric patients with Crohn's disease have significantly impaired expression of MHC class II molecules in comparison with control samples without IBD, which correlated with increased local frequencies of inflammatory T cells and systemic titres of antibodies targeting the microbiota 69 . MHC class II expression was increased or unchanged on intestinal T cells or DCs, respectively, and these findings were subsequently independently verified in a cohort of adult patients with IBD 123 . Finally, we also described a marked decrease in the level of ILC3-derived IL-2 in the small intestine of patients with Crohn's disease and identified a positive correlation between ILC3 and T reg cell frequencies 64 . As such, most studies so far implicate a protective role for ILC3s in orchestrating immune homeostasis in the intestine through multiple distinct mechanisms, as well as a substantial impairment of ILC3 responses in patients www.nature.com/nri with IBD. Therefore, therapies aimed at restoring normal ILC3 numbers and responses may hold an important key to maintaining intestinal health in humans, in part by controlling pro-inflammatory T cell responses and homeostasis with the microbiota.
Other gastrointestinal pathologies. Dysregulated communication between ILC3s and T cells may underlie other
gastrointestinal pathologies that result from infection, dietary changes or clinical interventions. For example, ILC3 numbers and responses are significantly impaired in the intestine following HIV-1 infection in humans or simian immunodeficiency virus infection in rhesus macaques 124, 125 . This could subsequently lead to increased CD4 + T cell activation through the impairment of IL-22mediated intestinal barrier function and the loss of direct T cell regulation by antigen-presenting ILC3s or IL-2producing ILC3s, which would collectively contribute to CD4 + T cell decline and progression to AIDS 126 . Similarly, increased circulating levels of ILC3-like cells correlate with reduced susceptibility to graft-versus-host disease, which potentially implicates similar mechanisms of ILC3mediated regulation of T cells 127, 128 , although the changes in intestinal ILCs have not been extensively investigated.
Autoimmune disease.
Although the biology of ILCs has been mainly studied at mucosal barrier sites, the interplay between ILCs and adaptive immunity could have important implications for disease pathology in systemic tissues. Indeed, ILCs have been implicated in the pathogenesis of a range of autoimmune diseases. Arthritic diseases are classically characterized by the presence of circulating autoantibodies and are often associated with the development of ectopic tertiary lymphoid follicles. Dysregulated communication between T FH cells, peripherally induced T FH -like cells and B cells has been implicated in the generation of autoantibodies in rheumatoid arthritis 129, 130 . Intriguingly, it has been suggested that inflammatory T H 17 cell and T FH cell responses generated within the intestinal tract, and driven by the microbiota, can exacerbate arthritic disease 131, 132 . Furthermore, ILCs may also modulate adaptive immune responses that drive arthritic diseases, as they can promote the development of tertiary lymphoid structures, augment T H cell responses and control humoral immune responses. In line with a role for ILCs, juvenile idiopathic arthritis has recently been associated with mutations in the NFIL3 gene 133 , which encodes a key transcriptional regulator of ILC development 1, 2 . Also, ILC2 numbers are markedly increased in the joints and circulation of patients with arthritis, and ILC2s have an important role in limiting inflammatory responses in mouse models through the production of IL-4, IL-9 and IL-13 (reFs 134, 135 ); however, it remains unclear whether interactions between ILC2s and adaptive immunity occur in these contexts.
In the context of multiple sclerosis, RORγt-expressing ILC3-like cells have been reported in tertiary lymphoid aggregates within the brains of patients with progressive disease 136 . Increased numbers of circulating LTi-like ILC3s positively correlated with autoantibody titres in the cerebrospinal fluid of patients with multiple sclerosis, and ILC3 numbers were reduced in patients receiving monoclonal antibody therapies that targeted CD25 (reF. 137 ). These data implicate not only a role for ILCs in regulating adaptive immune responses in autoimmune disorders but also the potential for novel therapeutic strategies in inflammatory disease.
Allergic disease. ILC2 numbers or associated responses are increased during multiple types of allergic disease in humans, such as asthma, atopic dermatitis, nasal polyps, rhinosinusitis and chronic obstructive pulmonary disease [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] . However, a majority of these studies have yet to interrogate potential interactions between these altered ILC2 responses and the adaptive immune response, although these two pathways typically have similar patterns of induction. One study showed that human ILC2s express MHC class II molecules and process and present allergen-derived antigens to CD4 + T cells, resulting in the differentiation and expansion of T H 2 cell populations 20 . These studies suggest that targeting ILC2s in human disease may suppress multiple aspects of the overall type 2 immune response.
Cancer. The investigation of a role for ILCs in human cancer is at a very early stage. Initial reports have identified that ILCs are present in human colon, lung and breast tumours, where they are localized to lymphoid structures and express activation markers including MHC class II molecules [148] [149] [150] [151] . Furthermore, as highlighted above, ILCs express PD1 and PDL1 (reFs 95-97 ),
Box 2 | Perspectives and future challenges
• Innate lymphoid cells (IlCs) have been found to activate, regulate and inhibit adaptive immune responses. Although some reports may seem contradictory, the findings can be reconciled by taking into account the IlC subset involved, the anatomical location of the responses and the contextual nature of the interaction. • As the field moves forwards, there is an urgent need for new, specific genetic tools to target IlC subsets, and it will be important to carefully re-evaluate data side by side and taking into account the potential caveats of the approaches used. The investigation of interactions between group 1 IlCs and adaptive immune cells has so far been limited and should be explored further. • lineage-specific targeting of IlCs is the most appropriate approach for evaluating functional interactions with adaptive immunity in vivo. However, this is not possible in the context of human samples; rather, tissue-specific correlations and the use of ex vivo co-cultures should be explored. • It is important that studies carefully consider the heterogeneity and tissue location of ILC subsets, as well as the type of interacting B cell or T cell. In particular, the outcome of these interactions may differ within complex tissues such as the gastrointestinal tract, as the result of different properties imprinted by anatomical location, microbial colonization levels, barrier permeability, mucous organization or metabolite production. • The expression of co-stimulatory molecules can determine the outcome of a direct ILC-T cell interaction. However, relatively little is known about the signals that regulate expression of these molecules on IlCs, or whether the outcome also simultaneously requires antigen presentation by the IlC. • It remains unclear how IlCs acquire antigens for presentation. Although studies are limited, IlCs do not seem to be major phagocytic populations. Colocalization of IlC-like cells with subcapsular sinus macrophages in lymphoid tissues has been observed, leading to the hypothesis that macrophages might transfer antigen-containing membrane blebs to IlCs 159, 160 . Alternatively, IlCs found within tertiary lymphoid structures may acquire antigens from microfold cells 161 or from intestinal mononuclear phagocytes, as previously described for migratory dendritic cell populations 162 .
suggesting that these populations are modified by checkpoint blockade immunotherapies. The expression of co-stimulatory and co-inhibitory molecules by ILCs opens up new avenues for intervention by co-opting these immune checkpoint pathways. In support of this, a human regulatory ILC3-like population was reported to limit the effector activity of tumour-associated T cells in an NKp46-dependent manner 152 . Additional studies are required to determine the contribution of ILC-adaptive immune cell interactions in cancer and the role of ILCs in checkpoint blockade immunotherapy, including associated adverse events and long-term outcomes.
Therapeutic modulation of ILCs. The emergence of next-generation immunotherapeutics, such as monoclonal antibodies and small-molecule antagonists, has the potential to revolutionize intervention strategies in chronic inflammatory diseases by influencing ILC-adaptive immune cell interactions. Advancing our understanding of the transcriptional and signal transduction pathways that mediate ILC functions may present additional treatment opportunities. Indeed, we previously showed that small-molecule inhibitors of RORγt can have beneficial effects in mouse models of intestinal inflammation, as well as in samples from patients with IBD, through the suppression of T cell-driven inflammatory responses, while unexpectedly leaving the regulatory functions of ILC3s intact 153 . In addition, targeting inflammatory signalling pathways, such as JAK-STAT signalling, may prove beneficial in suppressing the pro-inflammatory roles of ILCs in a broad range of inflammatory diseases from arthritis to allergy 154, 155 . However, to successfully harness ILC-adaptive immune cell interactions to benefit human health, a more complete understanding of these pathways in human diseases is required (Box 2).
Summary
ILCs are increasingly appreciated to have key roles in immune responses during both health and disease. ILCs have many canonical roles through the production of effector cytokines at barrier tissue sites, but increasing evidence suggests that ILCs also modulate the wider immune response through functional interactions with adaptive immune cells. These interactions begin early in life to facilitate the formation of organized lymphoid tissues and they continue to have key roles after birth to promote tolerance to dietary antigens or the microbiota and to facilitate tissue homeostasis. In adulthood, ILCs mediate multiple effects on the adaptive immune system through complex communication with myeloid or stromal cell networks, through the provision of soluble factors to support regulatory populations or through direct cell-surface interactions, including the direct presentation of antigen to T cells. However, it is crucial to carefully consider the context in which ILCs and adaptive immune cells interact to fully understand the seemingly differential or contra dictory roles that have been ascribed to ILCs. For example, ILC3s suppress adaptive immune responses in the intestine and draining lymph nodes during homeostasis 25,68-70 but can promote peripheral B cell and T cell responses in the spleen following vaccination 45, 72 . In addition, ILC3s promote IgA responses through the secretion of lymphotoxin, which acts on stromal cells or DCs 42, 44 , but conversely ILC3s suppress IgA production through antigen presentation to T FH cells 25 . Finally, ILC3-derived IL-2 is required to support T reg cells in the small intestine but not the large intestine 64 , and antigen presentation by ILC3s conversely regulates IgA responses in the large intestine but not the small intestine 25 . Many of these differences are owing to the tissue-and context-specific nature of ILC interactions with adaptive immunity. The reasons for this compartmentalization of ILC3mediated communication remain unexplored, and there is an urgent need to increase our understanding of the tissue microenvironments in which different ILC populations interact with adaptive immune cells and the signals or cellular heterogeneity present within each tissue niche that instruct the function of ILCs.
Together, these findings suggest a broader and more nuanced role for ILCs throughout the lifetime in orchestrating tissue immune responses. Whereas the unifying feature of ILC communication with adaptive immunity in the context of health seems to be to promote tissue homeo stasis, the outcomes of ILC interactions with adaptive immune cells might be markedly altered in the context of ageing, infection or inflammation. Collectively, these interactions could provide an unprecedented opportunity to therapeutically target or harness ILC interactions with adaptive immunity to treat human disease.
Future challenges
The past decade of research on ILCs has moved at an extraordinary pace and yielded many exciting advances; however, the study of ILCs in modulating adaptive immunity is still in the early stages of development. Reports from multiple groups have identified many functional interactions, but the precise nature of the signals involved and the consequences of this crosstalk are highly context dependent. There are many challenges ahead for advancing our understanding of ILC-adaptive immune cell interactions, and additional considerations should be made for both existing and future studies (Box 2). Our current approaches to target ILCs in the presence of adaptive immunity remain limited, and there is an urgent need to develop novel tools and strategies in mouse models. Furthermore, many early approaches to interrogate these interactions will need to be revisited as technologies, and the appreciation of cellular heterogeneity, advance. For example, recent research identified that many studies of ILCs in human blood might have examined ILC-like progenitors rather than mature ILC populations 41 , and recent comprehensive investigations of ILC populations across human tissues have revealed important differences in terms of ILC distribution, phenotype and function 156 , which indicates the need to more carefully study ILCs in the appropriate anatomical location. We also do not currently understand how to accurately quantify human ILC heterogeneity, such as the identification of analogous LTi-like ILC3 subsets versus T-bet + ILC3s. Indeed, the expression of natural cytotoxicity www.nature.com/nri receptors, which is a defining marker of an ILC3 subset in mice, is potentially more reflective of the activation status of human ILCs 157 . Recent pioneering work on single-cell sequencing of these populations is paving the way towards better approaches to carrying out these studies 158 . Notwithstanding these limitations, it is clear from the promise of these early studies that ILCs are more than simply an innate counterpart to adaptive immunity and may have evolved as master regulators of adaptive immunity and tissue homeostasis.
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